Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Werner Scheithauer

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
British Journal of Cancer|May 31, 2022
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
The Lancet. Oncology|August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
International Journal of Cancer|October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trialJulian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
British Journal of Cancer|May 31, 2022
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
The Lancet. Oncology|August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
International Journal of Cancer|October 20, 2017
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trialJulian Walter Holch, Ingrid Ricard, Sebastian Stintzing, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
Pageof 9